Institute

Liste

Prof. Dr. Katja Schenke-Layland

Stages of career

since 2018 Director, NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

since 2018 Co-Editor-in-Chief, Tissue Engineering, Part B (Mary Ann Liebert)

since 2011 Full Professor (W3), Eberhard Karls University Tübingen (EKUT), Institute for Biomedical Engineering, Department of Medical Technology and Regenerative Medicine, Tübingen, Germany

2013 - 2018 Adjunct Associate Professor, UCLA, Dept. of Medicine/ Cardiology, Los Angeles, CA, USA

2016 - 2017 Director (interim, executive), Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Stuttgart, Germany

2010 - 2014 ATTRACT-Group Leader, Fraunhofer IGB, Stuttgart, Germany

2010 - 2013 Deputy Department Head, Fraunhofer IGB, Dept. of Cell and Tissue Engineering, Stuttgart, Germany

2008 - 2009 Assistant Research Professor, UCLA, Dept. of Medicine/ Cardiology, Los Angeles, CA, USA

2005 - 2008 Postdoctoral Research Fellow, UCLA, Cardiovascular Research Laboratories, Los Angeles/CA, USA

2004 - 2005 Postdoctoral Research Fellow, Children’s Hospital Los Angeles, Saban Research Institute, Los Angeles/CA, USA

2001 - 2004 PhD in Biology/ Cardiovascular Tissue Engineering, Friedrich Schiller University (FSU) Jena, Germany

1995 - 2000 M.Sc. in Biology, Sociology, Psychology, Friedrich Schiller University (FSU) Jena, Germany

Further Information: Schenke-Layland Lab

View CV

Liste

Dr. Thomas Joos

E thomas.joos@nmi.de

Stages of career

2013 - Present Deputy Director, NMI

2008 - 2014 Director Strategic Alliances, EDI GmbH, Reutlingen (part time)

2000 - 2017 Head of Biochemistry Department, NMI

1998 - 2000 Research Assistant, NMI

1994 – 1998 Postdoctoral research, Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen

1994 Ph.D. degree (Dr. rer. nat), Dept. of Cell Biology, Max Planck Institute for Developmental Biology, Tübingen (under Prof. P. Hausen; Topic: "Integrin-α5 during early embroygenesis of Xenopus laevis"

04–08 1988 Molecular biology practical, Biochemistry Dept., the Brandeis University“ (under Prof. Andrew Szent-Györgyi), Waltham, Massachusetts, USA

1984 – 1990 Study of Biochemistry, University of Tübingen

Dr. Joos is a member of the editorial board of "Drug Discovery Today", "Proteomics" and "Expert Review of Proteomics".
He is a member of the Scientific Advisory Board of the Plasma Proteomics Institute in Washington, DC, USA and a member of the Scientific Advisory Board of Myriad RBM Inc. in Austin, Texas, USA.

Dr. Joos is the author of >100 scientific papers. He is recognized worldwide as an expert and opinion leader in the technology field of biomarkers and their clinical applications and basic research.

Dr. Joos is co-founder of SIGNATOPE GmbH, Reutlingen. SIGNATOPE develops innovative protein tests with which biomarkers for organ damage and drug interactions can be detected in all pharma-relevant species.

View CV

Liste

The NMI is a member of the Innovation Alliance Baden-Württemberg. It is involved in application-oriented research at the interface between the life sciences and material science. An interdisciplinary team of scientists is developing new technologies for companies and public research sponsors in the areas of pharma and biotechnology, biomedical technology, and surface and materials technology.

Our commitment, professionalism and flexibility are visible in all areas of our work. We manage projects from start to finish – from the planning stage, through to evaluation if required. Our portfolio also includes subprojects and individual services such as consulting, technology assessment, applying for funding, and conceptual planning and coordination of projects. We also offer accredited testing services.

Do get in touch – we'll find a solution!

Foundation and Board of Trustees

The NMI is a non-profit foundation with the Board of Trustees functioning as a volunteer advisory committee. The purpose of the foundation is to present the results of scientific research to the business community with the intention of turning pure research into practical, economically-viable business projects.

Executive Committee of the Foundation

Prof. Dr. Katja Schenke-Layland, Chairwoman of the Foundation

Dr. Thomas Joos, Vice Chairman

Prof. Dr. Matthias Schwab, First Vice Chairman

Gabriele Sonntag, Second Vice Chairwoman

Board of Trustees

Dr. Wolfgang Epp, Chairman of the Board of Trustees, IHK Reutlingen

Prof. Dr. Eberhard Zrenner, Vice Chairman of the Board of Trustees, University of Tübingen

Dr. Michael Albiez, Carl Zeiss AG, Oberkochen

Prof. Dr. Michael Auer, Steinbeis-Stiftung für Wirtschaftsförderung (StW)

Dr. Georg Bischopink, Robert Bosch GmbH, Reutlingen

Dr. Dr. Saskia Biskup, CeGat GmbH, Tübingen

Prof. Dr. Karla Pollmann, President of the University of Tübingen
Represented by Prof. Dr. Peter Grathwohl, Vice Cancellor

Prof. Dr. Peter Gumbsch, Fraunhofer-Institute IWM, Freiburg

Thomas Keck, Mayor of Reutlingen
Represented by Roland Wintzen

Prof. Dr. Petra Kluger, University of Reutlingen

Dr. Andreas Leusch, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach

Dr. Caroline Liepert, Ministerium für Wissenschaft, Forschung und Kunst, Stuttgart

Prof. Dr. Bernd Pichler, University of Tübingen

Dr. Dirk Grafahrend, Freudenberg Performance Materials s.a.s., Colmar (FR)

Prof. Dr. Thilo Stehle, Universität Tübingen

Dr.-Ing. habil Katrin Sternberg, Aesculap AG